TIDMONC
RNS Number : 2009M
Oncimmune Holdings PLC
20 September 2021
20 September 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Agreement signed with leading global pharmaceutical company
to profile patients using ImmunoINSIGHTS service
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces it has signed an
autoantibody profiling agreement with a leading global
pharmaceutical company to evaluate the autoantibody profiles of
patient samples in various autoimmune diseases. The initial phase
of this project, including the reporting of profiled data, is
scheduled to complete by the end of calendar year 2021.
Under this agreement, Oncimmune will utilise its proprietary
NavigAID(TM) autoimmune disease characterisation panel to explore
the autoantibody profiles of patients with four key autoimmune
diseases, namely systemic lupus erythematosus, Sjögren's syndrome,
rheumatoid arthritis and sicca syndrome. Oncimmune's customised
autoimmune disease panel has been developed to explore the
mechanisms of action, disease stratification and response
prediction in clinical trials.
The programme is Oncimmune's second agreement with this global
partner, and further validates the value of Oncimmune's
autoantibody biomarker profiling technology in supporting
pharmaceutical and biotechnology companies in their clinical
development programmes.
Dr Adam M Hill, CEO of Oncimmune, said: "We are delighted that
this global pharmaceutical company has again chosen to partner with
Oncimmune, for our world class autoantibody biomarker profiling
technology and autoimmune expertise . We are confident that this
latest programme will form part of a larger and long-term
collaboration and we look forward to supporting their programmes in
immunology further through clinical development.
"Today's agreement further demonstrates the strength of our
ImmunoINSIGHTS service, the increasing recognition of Oncimmune's
expertise in autoimmune disease, and our partnering strategy. This
new contract is also a good illustration of the growing uptake of
our services, validating our decision to invest in the physical and
human infrastructure of our platform to increase capacity
significantly, with further pipeline conversion expected over the
coming months and beyond."
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
Singer Capital Markets (Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Nigel Birks
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue both from its portfolio of diagnostic products to
detect early-stage cancer and its contract discovery and
development service business whose platform delivers actionable
insights into therapies to the Company's pharmaceutical and biotech
partners .
Our understanding of the immune system enables us to harness its
sophisticated response to disease to detect cancer earlier and to
support the development of better therapies. The key to improving
cancer survival is early detection and better selection for
therapy. As a company, we are driven by our passion to improve
cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effectively targeted and safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune's diagnostic products business is located at its
laboratory facility in Nottingham, UK and its ImmunoINSIGHTS
service business at its discovery research centre in Dortmund,
Germany. The ImmunoINSIGHTS business development team are based in
the US and Oncimmune is seeking to replicate the Dortmund facility
in the US in the medium term.
For more information, visit www.oncimmune.com
What is ImmunoINSIGHTS?
The ImmunoINSIGHTS service business leverages Oncimmune's
technology platform and methodologies across multiple diseases, to
offer life-science organisations actionable insights for therapies
across the development and product lifecycle. Our core
immune-profiling technology is underpinned by our library of over
eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
What is NavigAID?
Oncimmune's NavigAID arrays are thoroughly validated containing
well defined antigen panels, largely encompassing markers of
interest for each of the disease types being investigated.
Our portfolio of panels includes out-of-the-box NavigAID arrays
for immuno-oncology, autoimmune and infectious diseases. These
validated panels are frequently used as the starting point for
collaborations with partners to add further markers of interest to
their specific therapy and its specific indication.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRLRMATMTMBBAB
(END) Dow Jones Newswires
September 20, 2021 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024